Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axogen, Inc. - Common Stock (NQ:AXGN)

31.39 +2.04 (+6.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Axogen, Inc. Announces New Leadership Appointments
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Second Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Earnings Preview ↗
 
Via Benzinga
News headline image
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
Via Benzinga
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
News headline image
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
News headline image
Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Applied Therapeutics, Inc. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Greenbrier Posts Upbeat Earnings, Joins Kura Sushi USA, AxoGen And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply during Friday’s session following upbeat... 
Via Benzinga
Topics Stocks
News headline image
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Promotions on Research and Development Team
Company Also Announces Departure of Angelo Scopelianos, Ph.D. 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors 
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.